Navigation Links
Study points to potential new use for Viagra
Date:8/26/2008

(Kingston, ON) A "basic science" breakthrough by Queen's University researchers into regulating a single enzyme may lead to new drug therapies that will help prevent heart attacks and strokes.

Led by professor of Pharmacology and Toxicology Donald Maurice, the study focuses on the effects of Viagra the popular erectile dysfunction drug, which is also used to treat pulmonary hypertension.

The team's findings will be published on-line this week in the international journal Proceedings of the National Academy of Sciences (PNAS).

"As scientists, we're excited about this discovery because it's a fundamentally new approach to regulating what enzymes do in cells," says Dr. Maurice, a Career Scientist with the Ontario Heart and Stroke Foundation. "The fact that it also offers a potentially novel use of a drug already widely in use for other applications is an unexpected bonus."

The enzyme targeted by the Queen's researchers is known to regulate the activity of platelets: small blood cells needed for normal blood clotting. Problems can arise when people have stents permanently implanted in their arteries to maintain blood flow. Their platelets sometimes bind to the stent and, if enough platelets accumulate to form a blockage, this may cause a sudden, massive heart attack or stroke to occur.

Drugs like Viagra have been shown to inhibit PDE5, explains Lindsay Wilson, a PhD student in Pathology and Molecular Medicine and first author on the study. Until now, however, it hasn't been possible to isolate the small "pool" of activity within the cell where this is occurring.

The Queen's study shows that within each cell there are two different pools of the PDE5 enzyme, but that only one of them regulates platelet activation. "Understanding how the cell works should allow us to affect the activity of enzymes in one neighborhood and leave alone their 'identical twins' in a different neighborhood in that cell," says Ms Wilson.

"The idea is to use a PDE5 inhibitor such as Viagra selectively to inhibit platelet function," she continues. We now know that not all the enzymes in the cell are doing the same job. Just like in real estate, it's all about the location!"


'/>"/>

Contact: Nancy Dorrance
nancy.dorrance@queensu.ca
613-533-2869
Queen's University
Source:Eurekalert  

Related biology news :

1. Unique study shows oil, gas seismic work not affecting Gulf sperm whales
2. ETH Zurich study on salmonella self-destruction
3. Researchers study facial structures, brain abnormalities to reveal formula for detection of autism
4. Childrens national co-leads nationwide study of landmark sickle cell treatment
5. Largest study of its kind implicates gene abnormalities in bipolar disorder
6. Sweets make young horses harder to train in Montana State study
7. Light receptors in eye play key role in setting biological clock, study shows
8. Researchers to study lyme-like illness in Texas
9. Study shows continued spread of dead zones
10. Studying volcanoes with balloons
11. Study reveals surprising details of the evolution of protein translation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study points to potential new use for Viagra
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
(Date:1/11/2016)... 11, 2016 Synaptics Incorporated (NASDAQ: SYNA ... announced that its ClearPad ® TouchView ™ ... two separate categories in the 8 th Annual ... Technology Breakthrough. The Synaptics ® TDDI solution enables ... chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... its flagship CytoSorb® blood filter to treat deadly ... the world, announced that CEO Dr. Phillip ... Source Capital Group,s 2016 Disruptive Growth & Healthcare ... company.  Conference Presentation Details: ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
(Date:2/4/2016)... ... 04, 2016 , ... Franz Inc. , an early ... has been recognized As “ Best in Semantic Web Technology - USA & ... America, it’s our priority to showcase prominent professionals who are excelling in their ...
(Date:2/3/2016)... SAN DIEGO , Feb. 3, 2016 /PRNewswire/ ... medicine company with the first pluripotent stem cell-derived ... 1 diabetes in clinical-stage development, today announced that ... Janssen Pharmaceutical Companies of Johnson & Johnson, have ... BetaLogics group into ViaCyte.  The agreement provides ViaCyte ...
Breaking Biology Technology: